Avance Clinical, a CRO for the biotech industry, has incorporated another 2,000 clinical sites across North America into its Clinical GlobalReady Site Partnership Network.
These sites, according to Advance Clinical's CEO Yvonne Lungershausen, will enhance the delivery of the company's clinical development services to their biotech clients.
Avance's Senior Site Specialist, Tina Schied, commented: "The team has individually reviewed these sites for quality, their advanced process capabilities, therapeutic area expertise and compliance, so our clients can be assured of the quality and patient access of such facilities; these are vital elements for a successful clinical programme,"
The company made this strategic move to cater to its growing client base in the US.
"US-based biotechs now make up more than 80% of our clientele, and our GlobalReady programme helps us to streamline the clinical development process."
"We also have a global regulatory affairs team, which can assist biotechs in navigating the complex regulatory landscape with confidence, while also supporting them with application submissions to the FDA, EMA and TGA."
The company can also run clinical operations for pre-clinical and clinical trials for GMO therapies, as they are an accredited cell and gene technology CRO.
